Today's sweep found no meaningful new drug approval or safety communication for neurology. The only item was a supplemental approval for a generic lamotrigine product on 5 August, which changes nothing clinically. The feeds cover FDA drug approvals and enforcement actions and do not reach AAN, EAN or Indian Academy of Neurology publications issued as web documents, nor CDSCO notices.
The substantive guidance is the updated American Academy of Neurology and American Headache Society practice guideline on pharmacologic migraine prevention in adults, published on 31 August. Its systematic review covers studies through June 2024 and appears as a companion publication.
What distinguishes this revision is that it addresses the questions clinicians actually face rather than only ranking drugs by efficacy. It gives recommendations on when to start a preventive at all, and then on which one to choose in specific situations: patients with fibromyalgia, obesity or hypertension; older adults; pregnancy and lactation; sex-related considerations in drug choice; and patients with medication overuse. It also covers how to assess whether a preventive is working, how to handle adverse effects, and — the part most often neglected — when and how to stop.
Read alongside today's head-to-head trial, the practical message is that comorbidity should drive the choice. The patient with obesity, the patient with hypertension and the patient planning pregnancy each have a different right answer, and a guideline organised around those situations is more usable than one organised around drug classes.
- Choose a migraine preventive by comorbidity — obesity, hypertension, fibromyalgia and pregnancy plans each point to different agents
- Decide in advance what counts as success and when you will reassess, rather than continuing indefinitely by default
- Address medication overuse explicitly; a preventive started without tackling it will appear to fail
- Plan discontinuation as part of starting — the guideline covers stopping, which is routinely neglected
- Note the coverage gap: AAN, EAN and Indian Academy of Neurology guidance and CDSCO notices do not reach this feed
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free